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ABSTRACT
Macroautophagy/autophagy is critical for the regulation of pancreatic β-cell mass and its deregula-
tion has been implicated in the pathogenesis of type 2 diabetes (T2D). We have previously shown 
that treatment of pancreatic β-cells with the GLP1R (glucagon like peptide 1 receptor) agonist 
exendin-4 stimulates autophagic flux in a setting of chronic nutrient excess. The aim of this study 
was to identify the underlying pathways contributing to enhanced autophagic flux.
Pancreatic β-cells (INS-1E),mouse and human islets were treated with glucolipotoxic stress (0.5 
mM palmitate and 25 mM glucose) in the presence of exendin-4. Consistent with our previous work, 
exendin-4 stimulated autophagic flux. Using chemical inhibitors and siRNA knockdown, we identified 
RAPGEF4/EPAC2 (Rap guanine nucleotide exchange factor 4) and downstream calcium signaling to 
be essential for regulation of autophagic flux by exendin-4. This pathway was independent of AMPK 
and MTOR signaling. Further analysis identified PPP3/calcineurin and its downstream regulator TFEB 
(transcription factor EB) as key proteins mediating exendin-4 induced autophagy. Importantly, 
inhibition of this pathway prevented exendin-4-mediated cell survival and overexpression of TFEB 
mimicked the cell protective effects of exendin-4 in INS-1E and human islets. Moreover, treatment of 
db/db mice with exendin-4 for 21 days increased the expression of lysosomal markers within the 
pancreatic islets. Collectively our data identify the RAPGEF4/EPAC2-calcium-PPP3/calcineurin-TFEB 
axis as a key mediator of autophagic flux, lysosomal function and cell survival in pancreatic β-cells. 
Pharmacological modulation of this axis may offer a novel therapeutic target for the treatment of 
T2D.
Abbreviations: AKT1/protein kinase B: AKT serine/threonine kinase 1; AMPK: 5’ AMP-activated 
protein kinase; CAMKK: calcium/calmodulin-dependent protein kinase kinase; cAMP: cyclic adenosine 
monophosphate; CASP3: caspase 3; CREB: cAMP response element-binding protein; CTSD: cathepsin 
D; Ex4: exendin-4(1-39); GLP-1: glucagon like peptide 1; GLP1R: glucagon like peptide 1 receptor; GLT: 
glucolipotoxicity; INS: insulin; MTOR: mechanistic target of rapamycin kinase; NFAT: nuclear factor of 
activated T-cells; PPP3/calcineurin: protein phosphatase 3; PRKA/PKA: protein kinase cAMP activated; 
RAPGEF3/EPAC1: Rap guanine nucleotide exchange factor 3; RAPGEF4/EPAC2: Rap guanine nucleo-
tide exchange factor 4; SQSTM1/p62: sequestosome 1; T2D: type 2 diabetes; TFEB: transcription factor 
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Introduction
Macroautophagy/autophagy is a highly conserved pathway 
that serves to recycle unwanted or damaged organelles to 
provide energy to maintain intracellular homeostasis and sus-
tain core metabolic functions [1,2]. Fusion of the lysosomal 
and autophagosomal compartments is a critical step in the 
process and is highly dependent on lysosomal function [3]. 
Although classically considered a pro-survival mechanism 
active during nutrient deprivation, autophagy can also serve 
to remove superfluous nutrients, damaged/dysfunctional 
organelles or misfolded proteins, particularly in metabolically 
active tissues [4]. Accordingly, a role for autophagy in 
regulating cell survival in response to increased circulating 
nutrients has been proposed [5].
Pancreatic β-cells play a critical role in blood glucose 
homeostasis through the release of INS (insulin) in response 
to elevated glucose concentrations [6]. Failure of glucose to 
invoke an appropriate INS secretory response is central to the 
development of type 2 diabetes (T2D) [7] through 
a progressive decline of β-cell function, exhaustion and even-
tual β-cell demise [7,8]. Increased circulating nutrients parti-
cularly lipid, due to obesity and/or high fat diet, are major 
drivers in this process [9]. Due to high rates of protein 
synthesis, β-cells require robust degradation mechanisms for 
the disposal of misfolded/denatured proteins [10]. Autophagy 
appears critical for basal β-cell physiology and survival 
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because β-cell specific ablation of the key autophagic protein 
ATG7 caused accumulation of misfolded proteins/damaged 
organelles which was associated with decreased INS secretion 
and decreased β-cell mass [11,12]. Moreover, β-cell autophagy 
is also stimulated by excess nutrients [12–15] and studies 
using β-cell specific atg7 knockout mice show that autophagy 
is essential for the compensatory increase in β-cell mass in 
response to high-fat diet [12]. However, other studies [16,17] 
including our own [18], have shown that upon sustained 
nutrient excess, autophagic flux becomes impaired. This is 
consistent with the accumulation of autophagosomal struc-
tures in islets from T2D patients [18–20]. Continued stimula-
tion of this deregulated pathway eventually leads to 
accumulation of defective lysosomes, which can induce a pro- 
death stimulus [18]. In this setting, it is proposed that auto-
phagy is detrimental and therefore contributes to loss of 
functional β-cell mass [16–20].
Pharmacological approaches to restore autophagic flux 
have been shown to improve β-cell function/survival. 
Studies using rapamycin or carbamazepine to stimulate 
autophagy prevented palmitate-induced β-cell death 
[21,22]. However, global targeting of this ubiquitous path-
way is not recommended particularly since upregulation of 
autophagy is integral to the metastasis of many human 
cancers [23]. A more selective approach to target these 
pathways would be preferred. Recent research has identi-
fied GLP1R (glucagon like peptide 1 receptor) agonists, 
which are currently in clinical use for the treatment of 
T2D, as modulators of autophagy in several different tis-
sues [24], including β-cells [18,25,26]. Our recent study 
showed that treatment with the GLP1R agonist exendin-4 
(Ex4) restored the impairment in autophagic flux induced 
by nutrient excess through an improvement in lysosomal 
function and also stimulation of the autophagic pathway 
[18]. However, at present, the underlying pathways remain 
unidentified. The aim of the current study was to elucidate 
the pathways underlying the improvement in autophagic 
flux exerted by Ex4 in our β-cell model of nutrient excess.
Results
Signaling via RAPGEF/EPAC is essential for exendin-4 
mediated autophagy and β-cell survival
We first confirmed our prior findings [18] that in our β-cell 
model of nutrient excess (0.5 mM palmitate and 25 mM 
glucose, glucolipotoxicity [GLT]), Ex4 increased the conver-
sion of LC3-I to LC3-II, a marker of increased autophagy 
(Figure 1A). We next explored the signaling pathways 
involved in this regulation. GLP1R agonists are known to 
exert their anti-diabetic actions via the activation of numerous 
signaling pathways, with the PtdIns3K-AKT-MTOR axis 
being critical for their anti-apoptotic actions [27]. In our 
model, Ex4 increased the phosphorylation of AKT at Ser473 
(Figure 1B). Co-treatment with specific AKT inhibitor 
(Figure 1B) did not prevent the Ex4-mediated increase in 
LC3-II (Figure 1C) suggesting that the impact of Ex4 on 
autophagy is AKT-independent. We next explored a role for 
the cAMP pathway, which through its downstream targets 
PRKA/PKA (protein kinase cAMP activated) and RAPGEF4/ 
EPAC2 (Rap guanine nucleotide exchange factor 4) has been 
shown to be essential for the impact of GLP1R agonists on 
both β-cell function and survival [28–30]. In our model of 
nutrient excess, Ex4 increased cAMP production (Fig. S1A). 
Inhibition of PRKA using Rp-cAMPs, as confirmed by the 
decrease in phosphorylation of the PRKA target CREB (cAMP 
responsive element binding protein) (Figure 1D) failed to 
inhibit the Ex4-mediated increase in LC3-II (Figure 1E). In 
contrast, inhibition of the RAPGEF pathway using the 
RAPGEF3-RAPGEF4 inhibitor ESI-09 prevented the Ex4- 
mediated increase in LC3-II in INS-1E (Figure 1F), mouse 
(Figure 1G) and human islets (Figure 1H).
Previous studies have shown that RAPGEF4 is the predo-
minant isoform expressed in human pancreatic β-cells with 
minimal expression of RAPGEF3 [31]. We confirmed predo-
minant expression of RAPGEF4 over RAPGEF3 in mouse and 
human β-cells using published RNA datasets (Fig. S2) [32,33]. 
Application of a specific RAPGEF4 inhibitor, ESI-05 [34], 
showed a similar effect to ESI-09 and prevented the Ex4- 
induced increase in LC3-II (Figure 2A). We further explored 
a role for RAPGEF4 by siRNA silencing. Previous knockout 
mouse studies have shown the RAPGEF4 isoform A to be 
critical for the Ex4 induced stimulation of INS secretion [35]. 
We therefore downregulated RAPGEF4 protein in INS-1E 
cells using siRNA against Rapgef4 isoform-A (Figure 2B). 
There was no impact of RAPGEF4 downregulation on 
cAMP levels in response to Ex4 (Fig. S1B) suggesting that 
any impact is RAPGEF4 specific. Consistent with the 
RAPGEF4 inhibitor, siRNA downregulation prevented the 
Ex4-mediated increase in LC3-II (Figure 2C). To assess the 
impact on autophagic flux, we used INS-1E expressing 
mCherry-GFP-LC3 [18,27]. As previously described [18], 
treatment of INS-1E with GLT increased yellow puncta indi-
cating an impairment in flux. Co-treatment with Ex4 partially 
prevented this accumulation but this effect was reversed by 
RAPGEF4 downregulation (Figure 2D). Consistent with these 
findings, while treatment with Ex4 partially prevented the 
GLT-induced decrease in lysosomal CTSD (cathepsin D) 
staining, indicative of improved lysosomal function [18], this 
effect was prevented by downregulation of RAPGEF4 
(Figure 2E). These effects appear to be critical for the cyto-
protective effects of Ex4 since RAPGEF4 downregulation pre-
vented the Ex4-mediated decrease in GLT-induced cell death 
(Figure 2F). Importantly, the effect of Ex4 on both LC3-II 
(Figure 2G, H) and cell survival (Figure 2I, J) was mimicked 
by a non-isoform selective RAPGEF agonist (8-CPT-2Me- 
cAMP), and two RAPGEF4-specific agonists (Sp-8-BnT- 
cAMPS [S220] and Sp-8-BnT-2ʹ-O-Me-cAMPS [S223]) [36], 
further supporting a role for RAPGEF4 in this pathway.
Exendin-4 mediated autophagy is Ca2+-dependent
We next explored the downstream signaling pathways of 
RAPGEF4. Past research has shown the release of Ca2+ from 
intracellular stores to be a critical downstream component for 
RAPGEF4 signaling, particularly for the regulation of INS 
secretion by GLP1R agonists [30]. Treatment of INS-1E with 
Ex4 increased intracellular Ca2+ levels (Figure 3A, S3A, and 
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S3B). Chelation of Ca2+ using BAPTA-AM prevented the Ex4- 
mediated increase in LC3-II (Figure 3B) and also the Ex4- 
mediated protection of lysosomal CTSD staining (Figure 3C). 
To confirm a role for Ca2+, we incubated INS-1E with iono-
mycin, which invokes Ca2+ release from intracellular stores 
[37]. As expected, ionomycin caused a dramatic increase in 
intracellular Ca2+ (Figure 3D and S3C) and also increased 
LC3-II compared to GLT alone (Figure 3E). These results 
support a role for Ca2+ downstream of RAPGEF4 in the Ex4- 
mediated stimulation of autophagy.
Existing research highlights a vital role for RAP1, a Ras- 
related GTPase, in intersecting RAPGEF4 with its down-
stream mediators including Ca2+signaling pathways, with 
RAP1 being essential for RAPGEF4-mediated INS secretion 
Figure 1. Exendin-4 stimulates autophagic flux via a PRKA-independent mechanism. (A) INS-1E treated with glucolipotoxicity (GLT, 25 mM glucose and 0.5 mM 
palmitate) without or with 100 nM Ex4 for 6 h. LC3 was analyzed by western blotting, quantified as LC3-II:GAPDH ratio. n = 6. (B and C) INS-1E were pre-incubated 
with 10 nM AKT inhibitor VIII (AKTi) for 1 h prior to the addition of glucolipotoxicity (GLT) without or with 100 nM Ex4 for 6 h. Changes in protein expression or 
phosphorylation were analyzed by western blotting, quantified relative to total AKT (B) or GAPDH (C). n = 5 (B) or 4 (C). (D) INS-1E were pre-incubated with 50 μM 
Rp-cAMPs for 1 h prior to the addition of 100 nM Ex4 for 30 min. p-CREB and total CREB were analyzed by western blotting and quantified as p-CREB/CREB ratio. 
n = 4. (E) INS-1E were pre-incubated with 50 μM Rp-cAMPs for 1 h prior to the addition of GLT -/+ Ex4 for 6 h. LC3 was analyzed by western blotting and quantified 
as LC3-II:GAPDH ratio. n = 6. (F-H) INS-1E (F), mouse (G), or human (H) islets were pre-incubated with 10 μM ESI-09 for 1 h prior to the addition of GLT -/+ Ex4 for 
either 6 (F) or 48 h (G and H). LC3 was analyzed by western blotting and quantified as LC3-II:GAPDH ratio. n = 4 (F and H) or 6 (G). Results are expressed as raw 
densitometry units corrected for the loading control as stated. All data are mean ± SEM of four to six individual experiments. Statistical analysis was performed using 
one-way (A, B, G, H) or two-way ANOVA (C, D, E, F) followed by Bonferroni’s post-hoc test. * P < 0.05, **P < 0.01 effect of GLT vs control; #P < 0.05, ##P < 0.01; ^ 
P < 0.05, ^^P < 0.01, ^^^P < 0.005 effect of inhibitor.
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by pancreatic β-cells [38]. We silenced Rap1 in INS-1E using 
siRNA against both Rap1a and Rap1b isoforms (Figure 3F, G). 
Under RAP1 protein downregulation, Ex4 failed to increase 
LC3-II levels in the presence of GLT (Figure 3H) and did not 
protect the cells from GLT-induced cell death (Figure 3I). 
However, because downregulation of RAP1 significantly 
increased LC3-II levels in control conditions (Figure 3H), 
we cannot conclusively confirm a role for RAP1 in mediating 
the Ca2+-dependent effects of Ex4 on autophagy.
Exendin-4 mediated autophagy is independent of the 
AMPK and MTOR pathways
We next explored the potential downstream mediators of Ex4- 
regulated autophagy. Stimulation of INS-1E with Ex4 in the 
presence of GLT increased phosphorylation of the master auto-
phagy regulator MTOR (mechanistic target of rapamycin kinase) 
(Figure 4A) and its downstream target RPS6 (ribosomal protein 
S6) (Figure 4B), consistent with activation of this pathway [2]. 
This is also consistent with the increase in p-AKT by Ex4 
(Figure 1B), an upstream activator of MTOR. Since the active 
form of MTOR inhibits autophagy [2], these findings suggest that 
Ex4 regulates autophagy via an MTOR-independent pathway.
5ʹ AMP-activated protein kinase (AMPK) can stimulate 
autophagy independently of MTOR [2] and activation of the 
CAMKK-AMPK pathway has been shown to be critical for 
the activation of autophagy in cardiomyocytes by an RAPGEF 
activator [39]. In our model, Ex4 increased phosphorylation 
of AMPK at Thr174 (Figure 4C). Chemical inhibition of 
AMPK using compound C (Figure 4D) markedly decreased 
the GLT-induced increase in LC3-I to LC3-II conversion 
(Figure 4E). However, Ex4 continued to increase LC3-II levels 
in the presence of AMPK inhibition (Figure 4E). To further 
exclude this pathway, the upstream regulator CAMKK was 
inhibited using STO-609 (Figure 4D). In the presence of this 
inhibitor, Ex4 continued to increase LC3-II (Figure 4F). These 
data suggest that Ex4 mediates autophagy via a mechanism 
that is independent of both AMPK and MTOR.
Signaling via PPP3/calcineurin is required for Exendin-4 
mediated autophagy and β-cell survival
Recent studies have uncovered a novel pathway of autopha-
gic regulation, which involves activation of PPP3/calcineurin 
through the release of lysosomal Ca2+ stores [40]. This acti-
vation of PPP3 causes dephosphorylation of TFEB (tran-
scription factor EB) causing its dissociation from 
a lysosomal complex and translocation to the nucleus 
where it induces transcription of genes involved in autopha-
gy and lysosomal biogenesis [40,41]. Since we have pre-
viously shown that the effect of Ex4 on autophagic flux is 
mediated by an improvement in lysosomal function [18], this 
pathway was explored. We first determined whether Ex4 
activated PPP3. Treatment of INS-1E cells caused transloca-
tion of the PPP3 downstream target, NFATC1 (nuclear fac-
tor of activated T cells 1), to the nucleus, which was 
prevented by a specific PPP3 inhibitor FK506 (Figure 5A). 
Inhibition of PPP3 using FK506 prevented the Ex4-induced 
increase in LC3-II in both INS-1E (Figure 5B) and in isolated 
human islets (Figure 5C). This was accompanied by loss of 
the protective effect of Ex4 over GLT-induced cell death 
(Figure 5D). We further explored a role for PPP3 using 
siRNA knockdown of Ppp3r1/calcineurin B1 (Figure 5E), 
which has previously been shown to be the predominant 
isoform in pancreatic β-cells [42]. PPP3R1 downregulation 
prevented the Ex4-mediated increase in LC3-II (Figure 5F), 
the Ex4-mediated increase in lysosomal CTSD staining 
(Figure 5G) and also the protective effects of Ex4 on cell 
survival (Figure 5H). These data support a role for PPP3R1 
in regulating Ex4-mediated autophagy.
Exendin-4 stimulates autophagy and confers survival via 
TFEB
In our previous study [18], we showed that treatment of β- 
cells with Ex4 increased TFEB translocation to the nucleus, 
which was accompanied by increased transcription of TFEB 
target genes. We confirmed in this study that the Ex4- 
mediated increase in TFEB translocation was inhibited by 
the PPP3 inhibitor FK506 (Figure 6A). Time course studies 
showed that co-treatment with Ex4 caused a time-dependent 
increase in TFEB translocation in comparison to GLT alone, 
with maximal effect at >8 h treatment (Figure 6B). To test 
whether TFEB is essential for Ex4-mediated autophagy, we 
downregulated TFEB protein expression using siRNA 
(Figure 6C). TFEB downregulation prevented the Ex4- 
mediated increase in LC3-II (Figure 6D) and the increase 
in lysosomal CTSD staining (Figure 6E). TFEB downregula-
tion also prevented the Ex4-mediated decrease in SQSTM1 
accumulation, a marker of deregulated autophagic flux 
(Figure 6F) and prevented the protective effects of Ex4 on 
cell survival (Figure 6G). This data supports a role for TFEB 
in regulating autophagic flux and mediating the cell- 
protective effects of Ex4.
We next tested whether Ex4 caused release of lysosomal 
Ca2+ since this intracellular source has been shown to be 
critical for the activation of TFEB [40]. Using a Ca2+ sensor 
that localizes to the lysosomal membrane [43], we revealed 
that treatment with Ex4 increased Ca2+ around the lysosomal 
membrane evidenced by a spike in GCaMP3-ML1 signal, 
consistent with release of Ca2+ from this compartment 
(Figure 6H, I, and S4). Ex4 also caused release of Ca2+ from 
the endoplasmic reticulum evidenced by a decrease in ER- 
GCaMP6-150 [44] signal (Fig. S5) as well increased Ca2+ 
intake across the plasma membrane evidenced by a spike in 
pGP-CMV-GCaMP6s [45] signal (Fig. S6). The effect of Ex4 
on the movement of Ca2+ occurred 25–35 s following the 
addition of Ex4 and was simultaneous with an increase in 
total intracellular Ca2+ as assessed using Rhod-2 [46].
TFEB overexpression protects β-cells from 
glucolipotoxicity-induced cell death
Independent studies have shown that activation of TFEB can 
provide protection from the effects of the metabolic syndrome 
by improving the capacity of the cell to upregulate autophagy 
[47,48]. We therefore determined whether overexpression of 
TFEB was able to protect β-cells from the cytotoxic effects of 
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Figure 2. Exendin-4 stimulates autophagic flux via RAPGEF4 signaling. (A) INS-1E were pre-incubated with 10 μM ESI-05 for 1 h prior to the addition of GLT -/+ Ex4 
for 6 h. LC3 was analyzed by western blotting and quantified as LC3-II:GAPDH ratio. n = 6. (B-F) INS-1E (B, C, E and F) or INS-1E stably expressing mCherry-GFP-LC3 
(D) were treated with scrambled siRNA (siScr) or siRNA against Rapgef4 isoform A (siRapgef4) for 48 h prior to treatment with GLT -/+ Ex4 for 4 (D), 6 (B and C) or 18 h 
(E and F). (B) RAPGEF protein was analyzed by western blotting and quantified as RAPGEF:GAPDH ratio. n = 6. (C) LC3 was analyzed by western blotting and 
quantified as LC3-II:GAPDH ratio. n = 4. (D) Autophagic flux was assessed by live cell imaging of mCherry-GFP-LC3 and quantified by measurement of co-localizing 
red and green (yellow) puncta using Volocity software. n = 5. (E) Lysosomal function was assessed by immunostaining for CTSD (green) and puncta intensity 
quantified using Blobfinder software. n = 5. (F) Cell death was assessed by PI-Hoechst staining and quantified as PI-positive cells relative to total cell number. n = 3. 
(G-J) INS-1E were treated with GLT -/+ 100 nM Ex4, 10 μM 8-CPT-2Me-cAMP (8-CPT), 10 µM Sp-8-BnT-cAMPS (S220) or 10 µM Sp-8-BnT-2ʹ-O-Me-cAMPS (S223) for 6 h. 
(G and H) LC3 was analyzed by western blotting and quantified as LC3-II:GAPDH ratio. n = 5. (I and J) Cell death was assessed by PI-Hoechst staining and quantified 
as positive cells relative to total cell number. n = 5. Results are expressed as raw densitometry units corrected for the loading control as stated or normalized to 
control and expressed as fold change. All data are mean ± SEM of three to six individual experiments. Statistical analysis was performed using an unpaired t-test (B) 
or a one-way (G and H) or two-way ANOVA (A, C, D, E, F, I, J) followed by Bonferroni’s post-hoc test. *P < 0.05, **P < 0.01, ***P < 0.005 effect of GLT; #P < 0.05 
effect of Ex4; ^P < 0.05, ^^P < 0.01, ^^^P < 0.005 effect of knockdown; ~P < 0.05, ~~P < 0.01, ~~~P < 0.005 effect of agonist. Scale bars: 10 µm.
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GLT treatment. We generated a stable INS-1E cell line expres-
sing GFP-TFEB (Figure 7A). GFP-TFEB translocated to the 
nucleus upon acute nutrient starvation and in response to 
GLT (Figure 7B), similar to that of endogenous protein [18]. 
GFP-TFEB expressing cells showed a greater increase in LC3- 
II in response to GLT compared to control non-GFP-TFEB 
expressing cells (Figure 7C). Similarly, expression of GFP- 
TFEB increased lysosomal CTSD staining and also prevented 
the GLT-induced decrease in CTSD (Figure 7D). Assessment 
of autophagic flux using a measure of SQSTM1 accumulation 
showed that expression of GFP-TFEB was able to partially 
prevent the impairment in autophagic flux induced by GLT, 
as demonstrated by decreased SQSTM1 accumulation 
(Figure 7E). Further to this, GFP-TFEB expression conferred 
improved cell survival when cells were challenged with GLT 
as evidenced by a decrease in the apoptotic marker cleaved 
CASP3 (Figure 7F) and also decreased total cell death mea-
sured via PI staining (Figure 7G). Expression of GFP-TFEB in 
human islets (Figure 7H) also improved the autophagic capa-
city of the islet as determined by increased LC3-I to LC3-II 
conversion in response to GLT (Figure 7I) and also decreased 
GLT-induced cell death (Figure 7J).
Exendin-4 increases lysosomal marker expression in 
a mouse model of diabetes
To confirm that the mechanism uncovered in our in vitro 
study is relevant in vivo, we explored the impact of Ex4 
treatment on autophagic and lysosomal markers in pancreatic 
islets from db/db mice, a rodent model of T2D. db/db mice 
were injected twice daily with Ex4 (25 nmol/kg body weight) 
for 21 d, with lean non-diabetic C57Bl/6 J mice used as non- 
diabetic controls. Glucose and INS tolerance data from this 
study has previously been published and shows that Ex4 
treatment improved glucose tolerance of the db/db mice 
(Figures 3 and Figure 4 in [49]). Immunofluorescence staining 
of pancreatic tissue from these mice showed that the db/db 
model had lower INS protein expression compared to the lean 
controls (Figure 8A, and S7), consistent with β-cell failure 
characteristic of this model. Islets from db/db mice also 
showed increased SQSTM1 accumulation within pancreatic 
islets suggestive of an impairment in autophagic flux 
(Figure 8B, and S7A). There was no significant change in 
TFEB or CTSD protein expression (Figure 8C, D, S7B, and 
S7C). Treatment of db/db mice with Ex4 showed a trend 
toward increased INS protein expression (Figure 8A), consis-
tent with the improved glucose tolerance. Ex4 treatment 
increased both TFEB and CTSD protein expression 
(Figure 8C, D), suggestive of improved lysosomal function. 
There was a trend toward decreased SQSTM1 puncta follow-
ing treatment with Ex4 although this effect was not significant 
(Figure 8B).
Discussion
The maintenance of a functional pancreatic β-cell mass is 
essential to prevent the inexorable progression of T2D toward 
the need for injected INS replacement and increased risk of 
the complications of chronic high glucose levels. 
Understanding how β-cell mass can be preserved is essential 
to enable identification of novel target pathways for the treat-
ment of T2D. Autophagy has been recognized as a potential 
target pathway since studies have shown that improving auto-
phagic capacity can improve both β-cell function and mass in 
models of T2D [21,22]. In the current study, we identify the 
RAPGEF4-Ca2+-PPP3/calcineurin-TFEB axis as a potential 
target to improve autophagic flux and β-cell survival 
(Figure 8E).
There are several independent reports of GLP1R agonists 
stimulating autophagy, both in pancreatic β-cells and other 
tissue types [18,24–26] but little detail has been provided on 
the underlying mechanisms. A recent study reported that 
treatment of mice with a DPP-4 inhibitor, which exerts its 
anti-diabetic actions via inhibition of the rapid degradation of 
endogenous GLP-1 (glucagon like peptide 1), decreased phos-
phorylation of MTOR suggesting inhibition of MTOR activity 
and subsequent stimulation of autophagy [26]. In our model 
system, treatment with Ex4 increased MTOR signaling, con-
sistent with the current dogma that GLP1R agonists stimulate 
the MTOR pathway to promote proliferation [50,51] but does 
not support a role for MTOR in mediating GLP1R agonist- 
stimulated autophagy. Another study reported a potential role 
for AMPK in the regulation of autophagy by the GLP1R 
agonist liraglutide [52] whereby it was proposed that liraglu-
tide stimulated autophagy via the inhibition of AMPK. This is 
surprising because activation of AMPK usually stimulates 
autophagy [2]. In our study, we show that treatment of INS- 
1E cells with Ex4 did not inhibit AMPK but rather caused 
a small stimulation in phosphorylated AMPK. Furthermore, 
inhibition of AMPK using a chemical inhibitor did not pre-
vent the Ex4-mediated increase in LC3-II. However, it should 
be noted that this inhibitor caused a marked decrease in the 
GLT-induced increase in LC3-II, which made this analysis 
difficult and prevents complete exclusion of this pathway.
The pro-survival effects of GLP1R agonists in β-cells have 
largely been attributed to signaling via the AKT-MTOR axis 
through inhibition of apoptosis although a role for cAMP- 
dependent mechanisms have also been reported [28,29]. Our 
data excludes a role for AKT, MTOR and PRKA in mediating 
Ex4-induced autophagy but identifies a novel role for RAPGEF4 
in mediating Ex4-induced autophagy and its pro-survival effects. 
While RAPGEF4 is known to be critical for the potentiation of 
glucose-induced INS secretion by GLP-1 in β-cells [28,30], its 
cyto-protective role has largely been unexplored, unlike in the 
heart where the role for RAPGEF3 is well described [53]. Here, 
we provide strong evidence for RAPGEF4-mediated regulation 
of autophagy and cell survival as indicated by: i) prevention of 
Ex4-mediated autophagy in INS-1E by downregulation of 
RAPGEF4; ii) inhibition of Ex4-mediated autophagy by    
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Figure 3. Exendin-4 stimulates autophagy via calcium signaling. (A) INS-1E were pre-incubated with 2 μM Fluo-8 AM for 35 min followed by 20 min washout with 
Krebs-HEPES. Cells were stimulated with either 15 mM glucose (media) or 15 mM glucose + 100 nM Ex4. Changes in fluorescence were detected by fluorescence 
microscopy and expressed as ΔF/F0. Graphs are representative of four individual experiments. (B and C) INS-1E were pre-incubated with 10 μM BAPTA-AM for 1 h 
prior to the addition of GLT -/+ Ex4 for either 6 (B) or 18 h (C). (B) LC3 was analyzed by western blotting and quantified as LC3-II:GAPDH ratio. (C) Lysosomal function 
was assessed by immunostaining for CTSD and puncta intensity quantified using Blobfinder software. Results are normalized to control and expressed as fold change. 
n = 6 (B) or 5 (C). (D) INS-1E were pre-incubated with 2 μM Fluo-8 AM for 35 min followed by 20 min washout with Krebs-HEPES. Cells were stimulated with 1 μM 
Ionomycin (Iono) and analyzed as described in (A). Graph is representative of three experiments. (E) INS-1E were treated with GLT -/+ Ex4 or 1 μM Ionomycin for 6 h. 
LC3 was analyzed by western blotting, quantified as LC3-II:GAPDH ratio and expressed relative to control. n = 6. (F-I) INS-1E were treated with scrambled siRNA (siScr) 
or siRNA against Rap1a and Rap1b (siRap1ab) for 48 h prior to treatment with GLT -/+ Ex4 for 6 (H) or 18 h (I). (F) Rap1 mRNA expression was analyzed by RT-PCR and 
quantified as either Rap1a or Rap1b corrected for Ppia/cyclophilin a and expressed as % of siScr control. n = 4. (G) RAP1 protein expression was analyzed by western 
blotting using an antibody specific for both RAP1A and RAP1B isoforms. RAP1 expression is quantified as RAP1:GAPDH ratio. n = 6. (H) LC3 was analyzed by western 
blotting and quantified as LC3-II:GAPDH ratio. n = 5. (I) Cell death was assessed by PI-Hoechst staining and quantified as PI positive cells relative to total cell number. 
n = 6. Results are expressed as raw densitometry units corrected for the loading control as stated or normalized to control and expressed as fold change. All data are 
mean ± SEM of three to six individual experiments. Statistical analysis was performed using an unpaired t-test (F and G), or a one-way (E) or two-way ANOVA (B, C, 
H, I) followed by Bonferroni’s post-hoc test. *P < 0.05, ***P < 0.005 effect of GLT; #P < 0.05 effect of Ex4; ~P < 0.05 effect of Iono, ^^^P < 0.05 effect of knockdown. 
Scale bars: 10 µm.
AUTOPHAGY 7
RAPGEF inhibitors in INS1E and in mouse and human islets; iii) 
stimulation of autophagy and increased cell survival in INS-1E 
by RAPGEF4 specific agonists. These findings are consistent 
with the induction of autophagy by an RAPGEF agonist in 
cardiomyocytes [39]. However, RAPGEF-regulated autophagy 
appears complex since signaling through this pathway has been 
shown to inhibit autophagy in response to alpha-hemolysin via 
activation of CAPN (calpain) [54] as well as during chronic 
stimulation of β-cells with oleate where RAPGEF4 inhibition 
was necessary for the oleate-mediated increase in autophagy 
[55]. These studies parallel the complex regulation of autophagy 
by its downstream mediator Ca2+ [56] and demonstrates that the 
regulation of autophagy by this pathway appears to be both cell- 
type and stimulus specific, and thus warrants careful examina-
tion. It should be noted that while our data supports a role for 
the RAPGEF4 isoform in the Ca2+-PPP3/calcineurin-TFEB axis, 
the use of ESI-09 does not allow us to identify the RAPGEF 
isoform in the human islets studies since this inhibitor acts on 
both RAPGEF3 and RAPGEF4. However, using existing RNA 
datasets of mouse and human origin [32,33], we replicate pre-
vious studies in human islets [31] suggesting that RAPGEF4 is 
the predominant isoform in pancreatic β-cells, with little expres-
sion of RAPGEF3. This is consistent with our data showing that 
the Ex4-dependent effects on autophagy are prevented by the 
RAPGEF4 selective inhibitor ESI-05 and can be mimicked by 
RAPGEF4 selective agonists. Combined, these findings support 
a role for RAPGEF4 rather than RAPGEF3 in this mechanism.
After excluding the canonical MTOR and AMPK signaling 
pathways, we uncovered a novel role for the PPP3/calcineurin- 
TFEB axis in the Ex4-mediated stimulation of autophagy. 
Previous studies have reported activation of this pathway by 
starvation and exercise [40,41] via a mechanism that involves 
the release of lysosomal Ca2+, which activates PPP3 and subse-
quently TFEB localized to this compartment [40]. Some studies 
have reported upregulation of the PPP3-TFEB pathway in the 
absence of changes to lysosomal Ca2+suggesting that an increase 
in total intracellular Ca2+ may be sufficient [47]. Our data 
showed that treatment of INS-1E cells with Ex4 increased intra-
cellular Ca2+, which was associated with release of endoplasmic 
reticulum Ca2+ stores, increased uptake of Ca2+ across the 
plasma membrane and also increased movement of Ca2+ across 
the lysosomal membrane. This may represent release of Ca2+ 
from the lysosomal compartment but could also represent refill-
ing of this compartment [43]. The finding that Ex4 increases the 
localization of Ca2+ around the lysosomes is consistent with 
activation of TFEB via the previously described mechanism 
[40]. Studies in β-cells have reported activation of PPP3 and 
its downstream target NFAT by GLP-1 [57]. However, a recent 
study in human islets isolated from either juvenile or adult 
donors showed that while Ex4 stimulated proliferation via 
a PPP3-mediated pathway in juvenile islets, this effect was 
absent in adult islets [58]. In the current study, we confirmed 
that PPP3 was essential for the Ex4-mediated increase in auto-
phagy in human islets isolated from adult donors using 
a specific PPP3 inhibitor. It may be that while the downstream 
pathway of NFAT activation, which serves to stimulate cellular 
proliferation is lost in the adult islets, the upstream activation of 
PPP3 may be retained, consistent with the preservation of the 
GLP-1 signaling pathways influencing INS secretion in the adult 
model [58]. It should be noted that in a model of tacrolimus 
(also designated FK506) -induced diabetes, Ex4 continued to 
promote cell survival despite continued PPP3 inhibition [59]. In 
this in vivo model, Ex4 increased β-cell survival through 
improvements in lysosomal function, which promoted autop-
hagosomal-lysosomal fusion. Interestingly, in this model Ex4 
failed to stimulate autophagy, which is consistent with the 
inhibition of Ex4-mediated autophagic stimulation by PPP3 
inhibition in our model (Figure 5D, F) although in our hands 
this blockage also prevented the Ex4-mediated improvement in 
lysosomal staining. It is likely that the ability of Ex4 to act on the 
autophagy-lysosomal cascade is dependent on the external stres-
ses deregulating the pathway, i.e. tacrolimus vs chronic GLT. It 
may be that Ex4 improves lysosomal function via a PPP3- 
independent mechanism, in addition the PPP3-TFEB axis 
uncovered in our model.
The lysosomal transcription factor TFEB is essential for the 
appropriate regulation of autophagic flux and lysosomal biogen-
esis [40,41]. In the current study using both siRNA downregula-
tion of endogenous TFEB and overexpression of TFEB, we 
provide persuasive evidence highlighting an essential role for 
TFEB in Ex4-mediated autophagy and its pro-survival effects. 
These data are consistent with a previous study showing that 
overexpression of TFEB partially prevented palmitate-induced 
β-cell death [60] and a recent study linking GLP-1 signaling with 
TFEB regulation in hepatocytes [61]. Importantly, we have con-
firmed that expression of TFEB and its downstream target CTSD 
are upregulated following treatment of db/db mice with Ex4 
in vivo, which correlated with a trend toward improved auto-
phagic clearance of SQSTM1. We have also shown that TFEB 
overexpression exerts protective effects in human islets. These 
studies were complicated by the low viability of human islets in 
all conditions due to the complexity and duration of the study. 
However, consistent and reproducible data were attained over 
a number of independent experiments showing that TFEB over-
expression in human islets stimulated autophagy and prevented 
GLT-induced cell death. A number of commercially available 
chemicals have been identified to induce TFEB activation in 
HeLa cells [47]. However, we were unable to detect any effect 
of digoxin, ikarugamycin or alexidine dihydrochloride on TFEB 
localization in our INS-1E model at concentrations that are not 
cytotoxic (results not shown). In an independent study, a novel 
TFEB activator improved the glucose tolerance and metabolic 
profile in genetically induced diabetes (ob/ob) and in diet- 
induced obesity mouse models [48]. However, the impact of 
this activator on β-cell function and survival remains to be 
fully explored. This is particularly relevant given the recent 
reports of decreased TFEB nuclear localization in pancreatic 
islets from patients with T2D [62]. The finding that improving 
lysosomal function using targeted nanoparticles has positive 
effects on β-cell function in a model of nutrient excess [63], 
supports the targeting of lysosomal function or biogenesis to 
improve lipid handling in T2D.
To conclude, we provide substantial evidence for a role of 
the RAPGEF4-Ca2+-PPP3-TFEB axis in the regulation of 
pancreatic β-cell autophagy and the pro-survival effects of 
Ex4. Importantly, we provide confirmation that these 
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Figure 4. Exendin-4 stimulates autophagy independently of MTOR and AMPK signaling. (A-C) INS-1E were treated with GLT -/+ Ex4 for 2 h. Western blotting was 
used to quantify p-MTOR (S2448) (A), p-RPS6 (S240/244) (B) and p-PRKAA/AMPKα (T174) (C) and quantified relative to total MTOR, RPS6 or PRKAA. n = 5 (A and C) or 
6 (B). (D) INS-1E were pre-incubated with 10 μM STO-609 or 10 μM Compound C for 1 h prior to the addition of 100 nM Ex4 for 1 h. p-PRKAA (T174) was analyzed by 
western blotting. Images are representative of three individual experiments. (E and F) INS-1E were pre-incubated with 10 μM STO-609 (E) or 10 μM Compound C (F) 
for 1 h prior to the addition of GLT -/+ Ex4 for 6 h. LC3 was analyzed by western blotting and quantified as LC3-II:GAPDH ratio. n = 3 (E) or 4 (F). Results are 
expressed as raw densitometry units corrected for the loading control as stated. All data are mean ± SEM of three to six individual experiments. Statistical analysis 
was performed using either a one-way (A, B, C) or two-way ANOVA (E and F) followed by Bonferroni’s post-hoc test. *P < 0.05, **P < 0.01 effect of GLT; #P < 0.05, 
###P < 0.005 effect of Ex4; ^P < 0.05, ^^^P < 0.005 effect of inhibitor.
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Figure 5. PPP3/calcineurin is essential for the cell protective effects of exendin-4. (A) INS-1E were incubated with 15 mM glucose and 100 nM Ex4, without or with 
100 nM FK506 for 0, 10 or 20 min. NFATC1 translocation was visualized using immunostaining. Nuclear to cytoplasmic (N:C) ratio was quantified using ImageJ. n = 3. 
Images are representative of three individual experiments. (B-D) INS-1E (B and D) or human islets (C) were pre-incubated with 100 nM FK506 for 1 h prior to the 
addition of GLT -/+ Ex4 for 6 (B), 16 (D) or 48 h (C). (B and C). LC3 was analyzed by western blotting and quantified as LC3-II:GAPDH ratio. (D) Cell death was assessed 
by PI-Hoechst staining and quantified as positive cells relative to total cell number. n = 3 (C), 5 (B), 6 (D). (E-H) INS-1E were treated with scrambled siRNA (siScr) or 
siRNA against Ppp3r1/calcineurin B1 (siPpp3r1) for 48 h prior to treatment with GLT -/+ Ex4 for either 6 h (E and F) or 18 h (G and H). (E) PPP3R1 protein was analyzed 
by western blotting and quantified as PPP3R1:GAPDH ratio. (F) LC3 was analyzed by western blotting and quantified as LC3-II:GAPDH ratio. (G) Lysosomal function 
was assessed by immunostaining for CTSD and puncta intensity quantified using Blobfinder software. (H) Cell death was assessed by PI-Hoechst staining and 
quantified as positive cells relative to total cell number. n = 4 (E, G, H) or 5 (F). Results are expressed as raw densitometry units corrected for the loading control as 
stated or normalized to control and expressed as fold change. All data are mean ± SEM of three to six individual experiments. Statistical analysis was performed using 
an unpaired t-test (E), or a two-way ANOVA (B-D, F-H) followed by Bonferroni’s post-hoc test. *P < 0.05, **P < 0.01, ***P < 0.005 effect of GLT; #P < 0.05, ##P < 0.01 
effect of Ex4; ^ P < 0.05 effect of inhibitor or knockdown. Scale bars: 10 µm.
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Figure 6. TFEB mediates the cell protective effects of exendin-4. (A and B) INS-1E were pre-incubated with 100 nM FK506 for 1 h prior to the addition of GLT -/+ Ex4 
for 6 (A) or 2–12 h (B). TFEB translocation was visualized using immunostaining and quantified as nuclear to cytoplasmic (N:C) ratio using ImageJ. (A) Results are 
representative of three individual experiments. (B) Mean ± SEM of two to four individual experiments. (C-G) INS-1E were treated with scrambled siRNA (siScr) or 
siRNA against Tfeb (siTfeb) for 48 h prior to treatment with GLT -/+ Ex4 for either 6 (C and D) or 18 h (E-G). (C) TFEB protein was analyzed by western blotting and 
quantified as TFEB:GAPDH ratio. (D) LC3 was analyzed by western blotting and quantified as LC3-II:GAPDH ratio. (E) Lysosomal function was assessed by 
immunostaining for CTSD and puncta intensity quantified using Blobfinder software. (F) Autophagic flux was assessed by immunostaining for SQSTM1 and puncta 
intensity quantified using Blobfinder software. (G) Cell death was assessed by PI-Hoechst staining and quantified as positive cells relative to total cell number. n = 4 
(C, D, F, G) or 5 (E). (H and I) INS-1E were transfected with GCaMP3-ML1 (GCaMP) for 24 h prior to addition of Rhod-2-AM (Rhod2) for 30 min followed by 30 min 
washout in Tyrode’s solution at 11 mM glucose. Cells were stimulated with 100 nM Ex4 (H) or media only (Bl) (I) for 90 s. Specificity of the construct was confirmed by 
addition of 400 μM glycyl-L-phenylalanine-beta-naphthylamide (GPN) followed by 66 mM CaCl2 (Ca
2+). Changes in fluorescence at Ex:490, Em:525 (for GCaMP) and 
Ex:550, Em:580 (for Rhod-2-AM) were detected by confocal microscopy (Nikon A1R) and expressed as ΔF/F0. Data is representative of five individual experiments. 
Results are expressed as raw densitometry units corrected for the loading control as stated or normalized to control and expressed as fold change. All data are mean 
± SEM of three to five individual experiments. Statistical analysis was performed using an unpaired t-test (C), or a two-way ANOVA (D-G) followed by Bonferroni’s 
post-hoc test. * P < 0.05, **P < 0.01, ***P < 0.005 effect of GLT; #P < 0.05 effect of Ex4; ^P < 0.05 effect of knockdown. Scale bars: 10 µm.
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pathways are conserved in adult human islets, supporting 
novel therapeutic approaches targeting this pathway to pre-
serve a functional pancreatic β-cell mass in T2D. Given the 
accumulating evidence supporting the application of GLP1R 
agonists for the treatment of other disease states, including 
other metabolic diseases and numerous neurological 
disorders [64] via mechanisms involving autophagy 
[61,65,66], these findings could have implications beyond 
the treatment of T2D.
Figure 7. TFEB overexpression protects β-cells from GLT-mediated cell death. (A-G) Stable INS-1E clones that were non-expressing (-) or GFP-TFEB-expressing (GFP- 
TFEB) cells were starved (ST) for 2 h in HBSS (A and B) or incubated with GLT for 6 (A-C, F) or 18 h (D, E and G). (A) Expression of GFP-TFEB was confirmed by 
western blotting for GFP. The differences in migration pattern upon starvation or addition of GLT represent dephosphorylation of TFEB, which alters the migration 
rate of the protein [40]. (B) GFP-TFEB translocation was confirmed in response to both starvation and GLT exposure. Images are representative of three individual 
experiments. (C) LC3 was analyzed by western blotting and quantified as LC3-II:GAPDH ratio. (D) Lysosomal function was assessed by immunostaining for CTSD and 
puncta intensity quantified using Blobfinder software. (E) Autophagic flux was assessed by immunostaining for SQSTM1 and puncta intensity quantified using 
Blobfinder software. (F) Cell death was assessed by western blotting for cCASP3. (G) Cell death was assessed by PI-Hoechst staining and quantified as positive cells 
relative to total cell number. n = 4 (D and E), 5 (F) or 8 (C and G). (H-J) Human islets were transfected with GFP-only (GFP) or pEGFP-N1-TFEB (GFP-TFEB) and islets 
cultured for 48 h before exposure to GLT for a further 48 h. (H) GFP expression and LC3 were analyzed by western blotting. (I) LC3 was quantified as LC3-II:GAPDH 
ratio. (J) Cell death was assessed by PI-Hoechst staining and quantified as % viability. n = 4 (J) or 5 (H and I). Results are expressed as raw densitometry units 
corrected for the loading control as stated or normalized to control and expressed as fold change. All data are mean ± SEM of four to eight individual experiments. 
Statistical analysis was performed using a two-way ANOVA followed by Bonferroni’s post-hoc test *P < 0.05, **P < 0.01, ***P < 0.005 effect of GLT; ^P < 0.05, 
^^P < 0.01, ^^^P < 0.005 effect of overexpression. Scale bars: 10 µm.
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Figure 8. Exendin-4 increases lysosomal marker expression in vivo. (A-D) db/db mice were injected twice daily with either saline or exendin-4(1–39) at 25 nmol/kg bw 
for 21 d as described in [49]. Aged matched lean control C57Bl/6 J mice treated with saline were used as non-diabetic controls. Pancreatic tissue was stained for INS 
(A), SQSTM1 (B), TFEB (C) and CTSD (D) and imaged using confocal microscopy. Results are expressed either as raw intensity (A) or corrected for INS positive area 
(B-D). n = 5 animals, 10–15 islets imaged per condition. Statistical analysis was performed using one-way ANOVA followed by Bonferroni’s post-hoc test. * P < 0.05, 
** P < 0.01, *** P < 0.005, **** P < 0.001. (E) Schematic representation of model. Ex4 activates ADCY (adenylate cyclase) through its G-protein coupled receptor 
which leads to the activation of cAMP. The downstream activation of RAPGEF4 then leads to an increase in intracellular Ca2+ concentration, which in turn stimulates 
PPP3R1/calcineurin activity and downstream dephosphorylation of TFEB. This causes translocation of TFEB to the nucleus and subsequent upregulated transcription 
of genes involved in autophagy and lysosomal biogenesis and upregulation of autophagic flux. Image created by Biorender.com.
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Materials and methods
Cell culture
INS-1E cells were cultured in RPMI-1640 media (Sigma 
Aldrich, R8758) containing 50 μM β-mercaptoethanol 
(Sigma Aldrich, M3148), 1 mM sodium pyruvate (Sigma 
Aldrich, S8636), 50 U/ml penicillin, 50 μg/ml streptomycin 
(Sigma Aldrich, P4333) and 5% FBS (Thermo Fisher 
Scientific, 11550356). Palmitate:BSA was prepared as in [18]. 
Cells were incubated with appropriate inhibitors or agonists 
as in Table S1.
For siRNA silencing INS-1E cells were transfected with appro-
priate siRNA against Rapgef4 isoform A (GE Healthcare, 
L-101689-02-0005), Rap1a and Rap1b (Sigma Aldrich, 
SASI_RN02_00198438, SASI_RN02_00114089), Ppp3r1/calci-
neurin B1 (Sigma Aldrich, SASI_Rn01_00105944) and Tfeb 
(Sigma Aldrich, SASI_Rn01_00063599) for 48 h using either 
Lipofectamine® RNAiMAX (Thermo Fisher Scientific, 13778030) 
or Mission siRNA transfection reagent (Sigma Aldrich, S1452) 
according to the manufacturer’s instructions. For assessment of 
autophagic flux, INS-1E cells stably expressing pBABE-puro 
mCherry-EGFP-LC3B (a gift from Jayanta Debnath [64] 
[Addgene, 22418]) were generated and imaged as previously 
described [18]. For assessment of TFEB overexpression, INS-1E 
cells were transfected with pEGFP-N1-TFEB (a gift from Shawn 
Ferguson [67] [Addgene, 38119]) and non-expressing (-) or 
expressing (+) cells selected using FACS cell sorting for GFP. 
INS-1E cells expressing GFP-TFEB were cultured in 400 μg/ml 
G418 (Alfa Aesar, J63871.AD) to maintain selection.
Human islets
Human islets were isolated from 8 adult non-diabetic donors 
in either the Clinical Islet Lab, University of Alberta, 
Canada; the Islet Isolation Center, University of 
Edinburgh; The Islet Isolation Facility, University of 
Oxford or the Newcastle University Transplant 
Regenerative Medicine Laboratory, with appropriate ethical 
approval. All procedures were fully compliant with the 
declaration of Helsinki 2013: the ethical principles for med-
ical research involving human subjects. The clinical data for 
associated with each islet preparation are summarized in 
Table S2. Islets were maintained in CMRL media (GE 
Healthcare, 15–110) containing 0.5% human serum albumin 
(Sigma Aldrich, H3667), 50 U/ml penicillin and 50 μg/ml 
streptomycin (Sigma Aldrich, P4333) for 24 h prior to treat-
ment. For expression of GFP-TFEB, human islets (500– 
1000 per condition) were washed with PBS (Sigma Aldrich, 
P4417) before incubation with 0.5x trypsin-EDTA solution 
(Sigma Aldrich, T3924) for 3 min at 37°C. After washing 
and resuspension in 2.5 ml of RPMI-1640 media (Sigma 
Aldrich, R8758) with 1% FBS (Thermo Fisher Scientific, 
11550356), 500 μl of DNA:lipofectamine complex (5 μg 
DNA to 15 μl Lipofectamine 2000 [Thermo Fisher 
Scientific, 11668027]) containing either GFP-TFEB [28] or 
the GFP-only vector (pEGFP-N1: Clontech, PT3027-5) was 
added to each well for 16 h. Media was then replaced by 
CMRL media for 36 h prior to 48 h treatment.
Rodent islet isolation
Islets were isolated from 8 to 10 week old C57BL/6 mice as 
previously described [18]. All procedures conformed to Home 
Office Regulations and approved by Newcastle University 
Ethical Committee.
In vivo studies
The methodology for the in vivo studies has previously been 
published [49]. Nine week old homozygous C57Bl/KsJ db/db 
mice received twice daily intraperitoneal injections of either 
0.9% (w:v) sodium chloride (db/db saline controls and C57Bl/ 
6 J lean controls), or Ex4(1–39) (25 nmol/kg body weight) for 
21 d. Pancreatic tissues were fixed in 4% paraformaldehyde 
for 48 h before embedding in paraffin wax. Tissue was sec-
tioned (4-µm thickness) prior to staining.
Cell death measurements
For PI-Hoechst staining, cells were incubated with 10 µg/ml 
propidium iodide (Sigma Aldrich, P4864) and 10 µg/ml 
Hoechst-33342 (Sigma Aldrich, 14533) for 20 min. Images 
were taken with a Nikon TE2000 (×20). For INS-1E, >1000 
cells were counted per condition and analysis performed 
using ImageJ software (NIH). Data is expressed as number 
of PI-positive cells per total cells (Hoechst positive). For 
human islets, 10 islets were imaged per condition and the 
percentage viability of the total islet area quantified using 
ImageJ software. Apoptosis was determined by western blot-
ting for cleaved CASP3.
Western blotting
Proteins were fractionated using 4–20% SDS-PAGE gels 
(Bio-Rad, 4568096, 4568093) and transferred to PVDF 
(Fisher Scientific, 10078559). Membranes were probed with 
primary antibody at 4°C overnight. The primary antibodies 
used in this study included anti-p-AKT (Ser473; Cell 
Signaling Technology, 4060), anti-AKT (Cell Signaling 
Technology, 4691), anti-p-PRKAA/AMPKα (Thr172; Cell 
Signaling Technology, 2531), anti-PRKAA/AMPKα (Cell 
Signaling Technology, 2532), PPP3/calcineurin (Novus 
Biologicals, 212306), anti-cleaved CASP3 (Cell Signaling 
Technology, 9661), anti-p-CREB (Ser133; Cell Signaling 
Technology, 9198), anti-CREB (Cell Signaling Technology, 
9197), anti-RAPGEF (Cell Signaling Technology, 4156), anti- 
GAPDH (Hytest, 5G4), anti-GFP (Santa Cruz Biotechnology, 
sc-9996), anti-LC3 (Sigma Aldrich, L7543), anti-p-MTOR 
(Ser2448; Cell Signaling Technology, 2971), anti-MTOR 
(Cell Signaling Technology, 2972), anti-RAP1 (Cell 
Signaling Technology, 2399), anti-p-RPS6 (Ser240/244; Cell 
Signaling Technology, 2215), anti-RPS6 (Cell Signaling 
Technology, 2217) and anti-TFEB (Bethyl Laboratories, 
A303). After incubation with secondary antibody conjugated 
to horseradish peroxidase (Agilent Dako, P044801; Thermo 
Fisher Scientific, 61–6520), bands were detected using 
enhanced chemiluminescence. Immunoblots were scanned 
using the Bio-Rad GS-800 calibrated densitometer. Blot 
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oversaturation was excluded by analysis with Quantity-one 
(Bio-Rad) software and Fiji (ImageJ) software and blots 
deemed to be within the linear range were used for 
quantification.
Real time RT-PCR
RNA was extracted using TRIzol (Thermo Fisher Scientific, 
15,596,026), and cDNA was synthesized from 1 µg RNA with 
Maloney murine leukemia virus (Promega Corporation, 
M1705). Real-time RT-PCR was performed as in [68] using 
custom-designed primers (Table S3). Relative mRNA levels 
were calculated by delta cycle threshold, corrected for Ppia/ 
cyclophilin a, and expressed relative to siRNA scrambled control.
Immunostaining
For staining of cells, INS-1E were plated onto coverslips were 
fixed with 4% paraformaldehyde and immunostaining per-
formed as in [18]. The primary antibodies used in this study 
included anti-CTSD (Santa Cruz Biotechnologies, SC-6487), 
anti-NFATC1 (BD Pharmingen, 556602) and anti-SQSTM1 
(Progen, GP62-C). Cells were imaged using a Nikon TE2000 
(×100). Lysosomal puncta as determined by CTSD puncta were 
quantified using Blobfinder software (Uppsala University, 
Sweden). TFEB and NFATC1 translocation were quantified by 
measurement of the mean pixel intensity for the nuclear and 
cytoplasmic compartments using ImageJ and the nuclear:cyto-
plasmic ratio calculated. For these calculations, >5 images were 
taken per condition for each independent experiment.
For immunostaining of tissue, indirect immunofluorescence 
staining was carried out as in [18]. The primary antibodies used 
in this study included anti-CTSD (Proteintech, 21327-1-AP), 
anti-INS (Dako, A0564), anti-SQSTM1 and anti-TFEB (Bethyl 
Laboratories, A303). Tissue was imaged using a Nikon Eclipse 
TE2000-S and 10–15 islets imaged per condition. The intensity 
of INS staining and SQSTM1, TFEB and CTSD puncta within 
INS positive areas was quantified using FIJI software.
cAMP determination
INS-1E cells were washed with Krebs-Ringer Buffer (135 mM 
NaCl, 5 mM KCl, 1 mM MgSO4, 0.4 mM K2HPO4, 5.5 mM 
glucose (VWR, 10117), 20 mM HEPES (Thermo Fisher 
Scientific, 15630–056), pH4.7) and pre-incubated in buffer 
for 30 min. Following further washing, cells were incubated 
at 16.7 mM glucose in the presence of 500 µM IBMX (Enzo 
Life Sciences, BML-PD140-0200) with or without 100 nM Ex4 
for 15 min before extraction into 200 µl of 0.1 mM HCl-0.5% 
Triton X-100 (Sigma Aldrich, X100). cAMP was determined 
using the Direct cAMP ELISA kit (Enzo Life Sciences, ADI- 
900-066) accordingly to the manufacturer’s instructions.
Ca2+ imaging
For total cell Ca2+ imaging, INS-1E cells were plated in black- 
walled, clear bottomed 96-well plates (Screenstar; Greiner- 
Bioone, 655866). After 24 h cells were loaded with 2 μM 
Fluo-8 AM (Abcam, ab142773) for 35 min, followed by 
20 min washout with Krebs-HEPES-Ca2+ buffer (119 mM 
NaCl, 4.74 mM KCl, 1.19 mM MgCl2, 2.54 mM CaCl2, 
1.10 mM KH2PO4, 25 mM NaHCO3, 10 mM HEPES, pH 
7.4). Fluorescence was imaged (Ex: 490, Em:525) using 
a Nikon Eclipse TE2000-S every 15 s for 4 min. For each 
image, 10 cells were selected and Ca2+ transients calculated as 
ΔF/F0 using ImageJ.
For organelle specific Ca2+ imaging, vectors expressing 
GCaMP3 targeted toward lysosome (GCaMP3-ML1) [43], 
endoplasmic reticulum (ER-GCaMP6-150, a gift from 
Timothy Ryan [Addgene, 86918] [44]) and plasma membrane 
(pGP-CMV-GCaMP6s, a gift from Douglas Kim & GENIE 
Project [Addgene, 40753] [45]) were used. INS-1E were plated 
in cell culture slides (Cellview; Greiner-Bioone, 543079) and 
transfected with the specified vector using lipofectamine 2000 
for 24 h. Cells were incubated with 2 μM Rhod-2-AM 
(Thermo Fisher Scientific, R1245MP) diluted in 10% pluronic 
F-127 (Sigma Aldrich, P2443) for 30 min followed by 
a 30 min washout in Tyrode’s solution (137 mM NaCl, 
2.7 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 0.2 mM Na2 
HPO4, 12 mM NaHCO3, 11 mM glucose, pH 7.4). INS-1E 
were imaged using a Nikon A1R confocal microscope for 
3 min, with readings every 0.5 s at Ex:490, Em:525 (for 
GCaMP) and Ex:550, Em:580 (for Rhod-2-AM). 3–10 cells 
were selected per image and Ca2+ transients calculated as 
ΔF/F0 using FIJI software.
Statistical analysis
Results are expressed as means ± SEM for the number of 
experimental replicates (minimum of three, maximum of 
eight). Statistical analysis was performed using GraphPad 
Prism using an unpaired Student’s two-tailed t-test, by one- 
way ANOVA using mixed effects analysis comparing all treat-
ments or by ordinary two-way ANOVA comparing all treat-
ments, as stated in the legend. ANOVA analysis were followed 
by Bonferroni’s multiple comparison test. P < 0.05 was 
deemed to be statistically significant.
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